KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (ONC) Equity Average (2016 - 2025)

Historic Equity Average for BeOne Medicines (ONC) over the last 10 years, with Q3 2025 value amounting to $3.9 billion.

  • BeOne Medicines' Equity Average rose 1613.38% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 1613.38%. This contributed to the annual value of $3.4 billion for FY2024, which is 1327.07% down from last year.
  • Latest data reveals that BeOne Medicines reported Equity Average of $3.9 billion as of Q3 2025, which was up 1613.38% from $3.6 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Equity Average registered a high of $6.0 billion during Q1 2022, and its lowest value of $3.4 billion during Q2 2024.
  • Moreover, its 5-year median value for Equity Average was $3.8 billion (2021), whereas its average is $4.1 billion.
  • As far as peak fluctuations go, BeOne Medicines' Equity Average skyrocketed by 10688.51% in 2021, and later tumbled by 2827.02% in 2023.
  • BeOne Medicines' Equity Average (Quarter) stood at $4.7 billion in 2021, then dropped by 4.75% to $4.5 billion in 2022, then decreased by 19.23% to $3.7 billion in 2023, then fell by 7.29% to $3.4 billion in 2024, then grew by 16.72% to $3.9 billion in 2025.
  • Its Equity Average was $3.9 billion in Q3 2025, compared to $3.6 billion in Q2 2025 and $3.4 billion in Q1 2025.